Evidence map›Paper›PMID 39777247›Full record

ArticleWorld journal of gastroenterology2025

Loss-of-function mutations of microRNA-142-3p promote

Xing-Hui Yu, Yan Xie, Jian Yu, Kun-Ning Zhang, Zhou-Bo Guo, Di Wang, Zhao-Xian Li, Wei-Qi Zhang, Yu-Ying Tan, Li Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xing-Hui YuSchool of Medicine, Nankai University, Tianjin 300192, China.
Yan XieTianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin First Center Hospital, Tianjin 300192, China.
Jian YuFirst Central Clinical School, Tianjin Medical University, Tianjin 300192, China.
Kun-Ning ZhangSchool of Medicine, Nankai University, Tianjin 300192, China.
Zhou-Bo GuoFirst Central Clinical School, Tianjin Medical University, Tianjin 300192, China.
Di WangFirst Central Clinical School, Tianjin Medical University, Tianjin 300192, China.
Zhao-Xian LiSchool of Medicine, Nankai University, Tianjin 300192, China.
Wei-Qi ZhangSchool of Medicine, Nankai University, Tianjin 300192, China.
Yu-Ying TanTianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin First Center Hospital, Tianjin 300192, China.
Li ZhangDepartment of Liver Transplantation, Tianjin First Center Hospital, Tianjin 300192, China.
Wen-Tao JiangSchool of Medicine, Nankai University, Tianjin 300192, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) has been a pervasive malignancy throughout the world with elevated mortality. Efficient therapeutic targets are beneficial to treat and predict the disease. Currently, the exact molecular mechanisms leading to the progression of HCC are still unclear. Research has shown that the microRNA-142-3p level decreases in HCC, whereas bioinformatics analysis of the cancer genome atlas database shows the

aimTo investigate the effects and mechanisms of microRNA-142-3p and

methodsIn this study, we grouped HCC patients according to their immunohistochemistry results of

resultsIn this study, we found that HCC patients with high expression of

conclusionLoss function of microRNA-142-3p induces cancer progression and immune evasion through upregulation of

Indexed as

Carcinoma, HepatocellularCell ProliferationDisease ProgressionDNA-Binding ProteinsGene Expression Regulation, NeoplasticLiver NeoplasmsMice, NudeMicroRNAsTranscription FactorsAnimalsApoptosisCell Line, TumorCell MovementFemaleHumansImmune EvasionDNA-Binding ProteinsMicroRNAsMIRN142 microRNA, humanTranscription FactorsApoptosisASH1LHepatocellular carcinomaImmune evasionMicroRNA-142-3pTumor immune microenvironment

Identifiers

PMID39777247
PMCPMC11684187

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.